7 completed. 5 Phase 2, 2 Phase 3, 1 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 5 | Completed 5 |
| Phase 3 | 2 | Completed 2 |
| Phase 1 | 1 | Completed 1 |
Follow ixmyelocel-T: new trials by email Literature Review of ixmyelocel-T trials Research Report on ixmyelocel-T
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| An Efficacy, Safety and Tolerability Study of Ixmyelocel-T Administered Via Transendocardial Catheter-based Injections to Subjects With Heart Failure Due to Ischemic Dilated Cardiomyopathy (IDCM) ixmyelocel-T, Placebo - Ischemic Dilated Cardiomyopathy (IDCM) | Phase 2 | Completed | Vericel Corporation | 114 | 2013-02-20 | 2021-05-27 |
| Cell Therapy for Craniofacial Bone Defects Ixmyelocel-T, Autogenous Bone Grafting - Cleft Palate, Trauma | Phase 1 / Phase 2 | Completed | University of Michigan | 18 | 2012-08-01 | 2017-05-04 |
| An Efficacy and Safety Study of Ixmyelocel-T in Patients With Critical Limb Ischemia (CLI) Ixmyelocel-T, Placebo - Critical Limb Ischemia | Phase 3 | Completed | Vericel Corporation | 41 | 2012-02-01 | 2021-05-27 |
| Use of Ixmyelocel-T (Formerly Catheter-based Cardiac Repair Cell [CRC]) Treatment in Patients With Heart Failure Due to Dilated Cardiomyopathy Ixmyelocel-T, Vehicle Control - Dilated Cardiomyopathy | Phase 2 | Completed | Vericel Corporation | 22 | 2009-12-01 | 2021-05-27 |
| Use of Ixmyelocel-T (Formerly Cardiac Repair Cell [CRC] Treatment) in Patients With Heart Failure Due to Dilated Cardiomyopathy (IMPACT-DCM) Ixmyelocel-T, Standard of Care - Dilated Cardiomyopathy | Phase 2 | Completed | Vericel Corporation | 40 | 2008-09-01 | 2021-05-27 |
| Ixmyelocel-T Treatment of Patients With Osteonecrosis of the Femoral Head Ixmyelocel-T, Standard of Care Only - Osteonecrosis | Phase 3 | Completed | Vericel Corporation | 11 | 2007-09-01 | 2019-10-21 |
| Use of Ixmyelocel-T (Formerly Vascular Repair Cells [VRC]) in Patients With Peripheral Arterial Disease to Treat Critical Limb Ischemia Ixmyelocel-T, Placebo - Peripheral Arterial Disease | Phase 2 | Completed | Vericel Corporation | 86 | 2007-04-01 | 2020-05-20 |
Cardiomyopathy, Dilated (2) · Chronic Limb-Threatening Ischemia (2) · Peripheral Vascular Diseases (2) · Cleft Palate (1) · Heart Failure (1) · Ischemia (1) · Osteonecrosis (1) · Peripheral Arterial Disease (1) · Wounds and Injuries (1)
Vericel Corporation (6) · University of Michigan (1)
United States (7) · Canada (1)
Amit Patel, MD (1) · Anthony J Comerota, MD (1) · Darnell Kaigler, DDS, PhD (1) · Marc Hungerford, MD (1) · Timothy Henry, MD (1)
PMID 25142002, PMID 21684715, PMID 22453769, PMID 27059887, PMID 35802393